Vaxart, Inc. Logo

Vaxart, Inc.

VXRT

(1.0)
Stock Price

0,62 USD

-71.84% ROA

-110.46% ROE

-1.91x PER

Market Cap.

178.039.249,00 USD

8.93% DER

0% Yield

-431.61% NPM

Vaxart, Inc. Stock Analysis

Vaxart, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Vaxart, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (25%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 PBV

The stock's PBV ratio (1.31x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

3 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

4 ROE

Negative ROE (-99%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-88.92%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Vaxart, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Vaxart, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Buy

Vaxart, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Vaxart, Inc. Revenue
Year Revenue Growth
1985 34.200.000
1986 43.700.000 21.74%
1987 43.100.000 -1.39%
1988 47.300.000 8.88%
1989 59.200.000 20.1%
1990 72.800.000 18.68%
1991 68.200.000 -6.74%
1992 82.400.000 17.23%
1993 101.600.000 18.9%
1994 164.700.000 38.31%
1995 202.000.000 18.47%
1996 239.900.000 15.8%
1997 228.700.000 -4.9%
1998 243.100.000 5.92%
1999 233.600.000 -4.07%
2000 228.783.000 -2.11%
2001 234.829.000 2.57%
2002 195.966.000 -19.83%
2003 176.570.000 -10.98%
2004 142.183.000 -24.19%
2005 108.055.000 -31.58%
2006 89.868.000 -20.24%
2007 0 0%
2008 0 0%
2009 10.489.000 100%
2010 35.005.000 70.04%
2011 14.838.000 -135.91%
2012 33.600.000 55.84%
2013 68.700.000 51.09%
2014 24.600.000 -179.27%
2015 9.300.000 -164.52%
2016 8.900.000 -4.49%
2017 5.839.000 -52.42%
2018 4.159.000 -40.39%
2019 9.862.000 57.83%
2020 4.046.000 -143.75%
2021 892.000 -353.59%
2022 107.000 -733.64%
2023 1.784.000 94%
2023 7.379.000 75.82%
2024 25.604.000 71.18%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Vaxart, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 16.700.000 100%
1997 19.100.000 12.57%
1998 21.800.000 12.39%
1999 15.500.000 -40.65%
2000 14.266.000 -8.65%
2001 15.330.000 6.94%
2002 21.096.000 27.33%
2003 29.040.000 27.36%
2004 59.551.000 51.24%
2005 57.788.000 -3.05%
2006 28.745.000 -101.04%
2007 18.841.000 -52.57%
2008 12.556.000 -50.06%
2009 16.490.000 23.86%
2010 26.078.000 36.77%
2011 17.765.000 -46.79%
2012 15.500.000 -14.61%
2013 17.500.000 11.43%
2014 19.800.000 11.62%
2015 26.300.000 24.71%
2016 28.300.000 7.07%
2017 12.355.000 -129.06%
2018 17.275.000 28.48%
2019 14.540.000 -18.81%
2020 19.863.000 26.8%
2021 48.749.000 59.25%
2022 81.054.000 39.86%
2023 60.008.000 -35.07%
2023 68.142.000 11.94%
2024 69.920.000 2.54%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Vaxart, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 13.600.000 100%
2013 6.900.000 -97.1%
2014 6.600.000 -4.55%
2015 5.600.000 -17.86%
2016 5.700.000 1.75%
2017 2.599.000 -119.32%
2018 6.681.000 61.1%
2019 6.187.000 -7.98%
2020 15.202.000 59.3%
2021 21.890.000 30.55%
2022 29.386.000 25.51%
2023 19.684.000 -49.29%
2023 22.584.000 12.84%
2024 20.708.000 -9.06%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Vaxart, Inc. EBITDA
Year EBITDA Growth
1985 2.000.000
1986 2.200.000 9.09%
1987 2.000.000 -10%
1988 2.600.000 23.08%
1989 2.100.000 -23.81%
1990 4.000.000 47.5%
1991 4.200.000 4.76%
1992 5.000.000 16%
1993 11.500.000 56.52%
1994 21.800.000 47.25%
1995 -3.300.000 760.61%
1996 18.300.000 118.03%
1997 9.700.000 -88.66%
1998 24.800.000 60.89%
1999 14.100.000 -75.89%
2000 9.346.000 -50.87%
2001 23.811.000 60.75%
2002 38.903.000 38.79%
2003 36.341.000 -7.05%
2004 -34.080.000 206.63%
2005 -91.335.000 62.69%
2006 -60.301.000 -51.47%
2007 -46.782.000 -28.9%
2008 -19.818.000 -136.06%
2009 -17.106.000 -15.85%
2010 -592.000 -2789.53%
2011 -9.331.000 93.66%
2012 -26.100.000 64.25%
2013 -7.500.000 -248%
2014 -6.800.000 -10.29%
2015 -24.800.000 72.58%
2016 -27.100.000 8.49%
2017 -8.735.000 -210.25%
2018 -16.536.000 47.18%
2019 -7.120.000 -132.25%
2020 -28.234.000 74.78%
2021 -61.669.000 54.22%
2022 -96.321.000 35.98%
2023 -60.356.000 -59.59%
2023 -78.847.000 23.45%
2024 -60.624.000 -30.06%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Vaxart, Inc. Gross Profit
Year Gross Profit Growth
1985 4.900.000
1986 6.300.000 22.22%
1987 5.100.000 -23.53%
1988 5.700.000 10.53%
1989 8.400.000 32.14%
1990 11.200.000 25%
1991 10.300.000 -8.74%
1992 14.000.000 26.43%
1993 22.800.000 38.6%
1994 34.000.000 32.94%
1995 53.900.000 36.92%
1996 65.900.000 18.21%
1997 54.900.000 -20.04%
1998 76.200.000 27.95%
1999 78.400.000 2.81%
2000 76.028.000 -3.12%
2001 82.216.000 7.53%
2002 76.029.000 -8.14%
2003 95.216.000 20.15%
2004 54.115.000 -75.95%
2005 40.838.000 -32.51%
2006 27.156.000 -50.38%
2007 0 0%
2008 0 0%
2009 8.501.000 100%
2010 31.054.000 72.63%
2011 13.375.000 -132.18%
2012 13.900.000 3.78%
2013 17.600.000 21.02%
2014 21.000.000 16.19%
2015 9.200.000 -128.26%
2016 -8.734.000 205.34%
2017 -6.516.000 -34.04%
2018 -13.116.000 50.32%
2019 -4.678.000 -180.38%
2020 -15.817.000 70.42%
2021 -47.857.000 66.95%
2022 -3.160.000 -1414.46%
2023 -58.224.000 94.57%
2023 2.879.000 2122.37%
2024 21.204.000 86.42%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Vaxart, Inc. Net Profit
Year Net Profit Growth
1985 1.000.000
1986 800.000 -25%
1987 500.000 -60%
1988 200.000 -150%
1989 800.000 75%
1990 2.200.000 63.64%
1991 2.200.000 0%
1992 -600.000 466.67%
1993 3.500.000 117.14%
1994 7.900.000 55.7%
1995 -17.600.000 144.89%
1996 13.300.000 232.33%
1997 -11.200.000 218.75%
1998 -21.800.000 48.62%
1999 3.300.000 760.61%
2000 4.359.000 24.29%
2001 104.682.000 95.84%
2002 2.055.000 -4994.01%
2003 -6.832.000 130.08%
2004 -50.390.000 86.44%
2005 -128.449.000 60.77%
2006 -58.703.000 -118.81%
2007 47.069.000 224.72%
2008 -18.738.000 351.2%
2009 -18.727.000 -0.06%
2010 878.000 2232.92%
2011 -4.531.000 119.38%
2012 -8.900.000 49.09%
2013 -11.000.000 19.09%
2014 -19.100.000 42.41%
2015 -25.400.000 24.8%
2016 -29.400.000 13.61%
2017 -12.460.000 -135.96%
2018 -18.007.000 30.8%
2019 -18.645.000 3.42%
2020 -32.220.000 42.13%
2021 -70.470.000 54.28%
2022 -107.758.000 34.6%
2023 -69.600.000 -54.82%
2023 -82.465.000 15.6%
2024 -65.864.000 -25.2%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Vaxart, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1985 7
1986 4 -133.33%
1987 2 -200%
1988 1 0%
1989 4 66.67%
1990 9 66.67%
1991 9 0%
1992 -3 550%
1993 -50 95.92%
1994 30 263.33%
1995 -35 188.24%
1996 25 236%
1997 -21 219.05%
1998 -41 48.78%
1999 7 783.33%
2000 8 14.29%
2001 182 96.15%
2002 3 -9000%
2003 -9 122.22%
2004 -57 83.93%
2005 -142 60.28%
2006 -64 -123.81%
2007 51 223.53%
2008 -24 321.74%
2009 -24 4.17%
2010 1 2500%
2011 -7 114.29%
2012 -3 -133.33%
2013 -4 0%
2014 -6 40%
2015 -7 28.57%
2016 -8 12.5%
2017 -92 91.21%
2018 -3 -4450%
2019 -1 0%
2020 0 0%
2021 -1 0%
2022 -1 0%
2023 0 0%
2023 -1 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Vaxart, Inc. Free Cashflow
Year Free Cashflow Growth
1985 0
1986 0 0%
1988 0 0%
1989 1.500.000 100%
1990 -900.000 266.67%
1991 -1.600.000 43.75%
1992 700.000 328.57%
1993 1.300.000 46.15%
1994 -7.300.000 117.81%
1995 -18.200.000 59.89%
1996 -16.900.000 -7.69%
1997 -62.000.000 72.74%
1998 -700.000 -8757.14%
1999 2.300.000 130.43%
2000 -9.172.000 125.08%
2001 10.999.000 183.39%
2002 -1.237.000 989.17%
2003 -64.110.000 98.07%
2004 -13.895.000 -361.39%
2005 -98.426.000 85.88%
2006 -44.135.000 -123.01%
2007 -26.854.000 -64.35%
2008 -18.954.000 -41.68%
2009 6.213.000 405.07%
2010 39.778.000 84.38%
2011 -15.167.000 362.27%
2012 -14.900.000 -1.79%
2013 -3.400.000 -338.24%
2014 -9.700.000 64.95%
2015 -14.300.000 32.17%
2016 -30.530.000 53.16%
2017 -10.157.000 -200.58%
2018 -15.255.000 33.42%
2019 -13.940.000 -9.43%
2020 -24.973.000 44.18%
2021 -64.989.000 61.57%
2022 -104.380.000 37.74%
2023 -15.283.000 -582.98%
2023 -72.324.000 78.87%
2024 -12.397.000 -483.4%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Vaxart, Inc. Operating Cashflow
Year Operating Cashflow Growth
1985 0
1986 0 0%
1988 0 0%
1989 2.800.000 100%
1990 500.000 -460%
1991 -200.000 350%
1992 2.900.000 106.9%
1993 3.000.000 3.33%
1994 -500.000 700%
1995 6.200.000 108.06%
1996 6.200.000 0%
1997 -25.600.000 124.22%
1998 18.200.000 240.66%
1999 23.300.000 21.89%
2000 9.811.000 -137.49%
2001 24.051.000 59.21%
2002 10.920.000 -120.25%
2003 7.542.000 -44.79%
2004 8.738.000 13.69%
2005 -89.714.000 109.74%
2006 -43.912.000 -104.3%
2007 -26.744.000 -64.19%
2008 -18.901.000 -41.5%
2009 6.217.000 404.02%
2010 39.932.000 84.43%
2011 -15.166.000 363.3%
2012 -13.900.000 -9.11%
2013 -3.300.000 -321.21%
2014 -9.600.000 65.63%
2015 -14.100.000 31.91%
2016 -30.000.000 53%
2017 -10.040.000 -198.8%
2018 -14.548.000 30.99%
2019 -13.090.000 -11.14%
2020 -23.750.000 44.88%
2021 -59.832.000 60.31%
2022 -94.779.000 36.87%
2023 -15.001.000 -531.82%
2023 -70.453.000 78.71%
2024 -12.027.000 -485.79%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Vaxart, Inc. Capital Expenditure
Year Capital Expenditure Growth
1985 0
1986 0 0%
1988 0 0%
1989 1.300.000 100%
1990 1.400.000 7.14%
1991 1.400.000 0%
1992 2.200.000 36.36%
1993 1.700.000 -29.41%
1994 6.800.000 75%
1995 24.400.000 72.13%
1996 23.100.000 -5.63%
1997 36.400.000 36.54%
1998 18.900.000 -92.59%
1999 21.000.000 10%
2000 18.983.000 -10.63%
2001 13.052.000 -45.44%
2002 12.157.000 -7.36%
2003 71.652.000 83.03%
2004 22.633.000 -216.58%
2005 8.712.000 -159.79%
2006 223.000 -3806.73%
2007 110.000 -102.73%
2008 53.000 -107.55%
2009 4.000 -1225%
2010 154.000 97.4%
2011 1.000 -15300%
2012 1.000.000 99.9%
2013 100.000 -900%
2014 100.000 0%
2015 200.000 50%
2016 530.000 62.26%
2017 117.000 -352.99%
2018 707.000 83.45%
2019 850.000 16.82%
2020 1.223.000 30.5%
2021 5.157.000 76.28%
2022 9.601.000 46.29%
2023 282.000 -3304.61%
2023 1.871.000 84.93%
2024 370.000 -405.68%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Vaxart, Inc. Equity
Year Equity Growth
1985 2.700.000
1986 6.100.000 55.74%
1987 8.000.000 23.75%
1988 8.300.000 3.61%
1989 9.700.000 14.43%
1990 12.100.000 19.83%
1991 15.100.000 19.87%
1992 13.900.000 -8.63%
1993 18.000.000 22.78%
1994 51.800.000 65.25%
1995 69.400.000 25.36%
1996 86.100.000 19.4%
1997 75.700.000 -13.74%
1998 54.200.000 -39.67%
1999 58.200.000 6.87%
2000 77.394.000 24.8%
2001 187.206.000 58.66%
2002 189.029.000 0.96%
2003 319.316.000 40.8%
2004 284.321.000 -12.31%
2005 161.827.000 -75.69%
2006 111.388.000 -45.28%
2007 146.532.000 23.98%
2008 121.382.000 -20.72%
2009 97.407.000 -24.61%
2010 60.570.000 -60.82%
2011 58.871.000 -2.89%
2012 68.000.000 13.43%
2013 86.900.000 21.75%
2014 69.500.000 -25.04%
2015 46.200.000 -50.43%
2016 18.700.000 -147.06%
2017 -38.722.000 148.29%
2018 11.238.000 444.56%
2019 12.952.000 13.23%
2020 123.404.000 89.5%
2021 187.531.000 34.2%
2022 110.597.000 -69.56%
2023 57.805.000 -91.33%
2023 71.521.000 19.18%
2024 80.014.000 10.61%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Vaxart, Inc. Assets
Year Assets Growth
1985 10.000.000
1986 13.400.000 25.37%
1987 13.600.000 1.47%
1988 20.900.000 34.93%
1989 24.400.000 14.34%
1990 23.700.000 -2.95%
1991 26.600.000 10.9%
1992 47.500.000 44%
1993 52.900.000 10.21%
1994 93.800.000 43.6%
1995 138.000.000 32.03%
1996 202.100.000 31.72%
1997 225.900.000 10.54%
1998 218.300.000 -3.48%
1999 214.600.000 -1.72%
2000 224.487.000 4.4%
2001 310.309.000 27.66%
2002 232.816.000 -33.29%
2003 387.301.000 39.89%
2004 368.171.000 -5.2%
2005 329.336.000 -11.79%
2006 265.877.000 -23.87%
2007 238.570.000 -11.45%
2008 144.221.000 -65.42%
2009 131.317.000 -9.83%
2010 113.871.000 -15.32%
2011 97.965.000 -16.24%
2012 85.800.000 -14.18%
2013 114.000.000 24.74%
2014 79.400.000 -43.58%
2015 72.700.000 -9.22%
2016 40.100.000 -81.3%
2017 4.523.000 -786.58%
2018 35.227.000 87.16%
2019 37.032.000 4.87%
2020 152.582.000 75.73%
2021 221.168.000 31.01%
2022 153.847.000 -43.76%
2023 91.830.000 -67.53%
2023 105.642.000 13.07%
2024 113.749.000 7.13%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Vaxart, Inc. Liabilities
Year Liabilities Growth
1985 7.300.000
1986 7.300.000 0%
1987 5.600.000 -30.36%
1988 12.600.000 55.56%
1989 14.700.000 14.29%
1990 11.600.000 -26.72%
1991 11.500.000 -0.87%
1992 33.600.000 65.77%
1993 34.900.000 3.72%
1994 42.000.000 16.9%
1995 68.600.000 38.78%
1996 116.000.000 40.86%
1997 150.200.000 22.77%
1998 164.100.000 8.47%
1999 156.400.000 -4.92%
2000 147.093.000 -6.33%
2001 123.103.000 -19.49%
2002 43.787.000 -181.14%
2003 67.985.000 35.59%
2004 83.850.000 18.92%
2005 167.509.000 49.94%
2006 154.489.000 -8.43%
2007 92.038.000 -67.85%
2008 22.839.000 -302.99%
2009 33.910.000 32.65%
2010 53.301.000 36.38%
2011 39.094.000 -36.34%
2012 17.800.000 -119.63%
2013 27.100.000 34.32%
2014 9.900.000 -173.74%
2015 26.500.000 62.64%
2016 21.400.000 -23.83%
2017 43.245.000 50.51%
2018 23.989.000 -80.27%
2019 24.080.000 0.38%
2020 29.178.000 17.47%
2021 33.637.000 13.26%
2022 43.250.000 22.23%
2023 34.025.000 -27.11%
2023 34.121.000 0.28%
2024 33.735.000 -1.14%

Vaxart, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.07
Net Income per Share
-0.41
Price to Earning Ratio
-1.91x
Price To Sales Ratio
14.51x
POCF Ratio
-2.34
PFCF Ratio
-2.85
Price to Book Ratio
1.81
EV to Sales
12.86
EV Over EBITDA
-2.29
EV to Operating CashFlow
-2.56
EV to FreeCashFlow
-2.53
Earnings Yield
-0.52
FreeCashFlow Yield
-0.35
Market Cap
0,18 Bil.
Enterprise Value
0,16 Bil.
Graham Number
2
Graham NetNet
0.18

Income Statement Metrics

Net Income per Share
-0.41
Income Quality
0.82
ROE
-1.14
Return On Assets
-0.43
Return On Capital Employed
-0.83
Net Income per EBT
1
EBT Per Ebit
1.01
Ebit per Revenue
-4.28
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
1.86
Research & Developement to Revenue
5.39
Stock Based Compensation to Revenue
1.16
Gross Profit Margin
-0.18
Operating Profit Margin
-4.28
Pretax Profit Margin
-4.3
Net Profit Margin
-4.32

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.33
Free CashFlow per Share
-0.34
Capex to Operating CashFlow
-0.01
Capex to Revenue
0.06
Capex to Depreciation
0.12
Return on Invested Capital
-0.86
Return on Tangible Assets
-0.72
Days Sales Outstanding
142.07
Days Payables Outstanding
284.62
Days of Inventory on Hand
0
Receivables Turnover
2.57
Payables Turnover
1.28
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,34
Book Value per Share
0,43
Tangible Book Value per Share
0.39
Shareholders Equity per Share
0.43
Interest Debt per Share
0.05
Debt to Equity
0.09
Debt to Assets
0.06
Net Debt to EBITDA
0.29
Current Ratio
4.54
Tangible Asset Value
0,07 Bil.
Net Current Asset Value
0,04 Bil.
Invested Capital
97142000
Working Capital
0,06 Bil.
Intangibles to Total Assets
0.07
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0.5
Debt to Market Cap
0.04

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Vaxart, Inc. Dividends
Year Dividends Growth
2012 0

Vaxart, Inc. Profile

About Vaxart, Inc.

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.

CEO
Mr. Steven Lo
Employee
109
Address
170 Harbor Way
South San Francisco, 94080

Vaxart, Inc. Executives & BODs

Vaxart, Inc. Executives & BODs
# Name Age
1 Dr. Sean N. Tucker Ph.D.
Senior Vice President & Chief Scientific Officer
70
2 Mr. Edward B. Berg
Senior Vice President & General Counsel
70
3 Mr. Steven Lo
President, Chief Executive Officer & Director
70
4 Dr. Rajesh Kapoor Ph.D.
Senior Vice President of Quality
70
5 Dr. James F. Cummings M.D.
Chief Medical Officer
70
6 Ms. Shaily Jaini Garg
Senior Vice President of Clinical Development & Project Management
70
7 Mr. Phillip Eric Lee
Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer
70
8 Dr. Raymond D. Stapleton Jr., Ph.D.
Chief Technology Officer
70

Vaxart, Inc. Competitors

iBio, Inc. Logo
iBio, Inc.

IBIO

(0.8)
Novavax, Inc. Logo
Novavax, Inc.

NVAX

(2.5)
Ocugen, Inc. Logo
Ocugen, Inc.

OCGN

(1.0)